Status:

COMPLETED

A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder

Lead Sponsor:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions:

Panic Disorder

Eligibility:

All Genders

20-64 years

Phase:

PHASE4

Brief Summary

To evaluate the efficacy and safety of sertraline compared to paroxetine in patients with panic disorder.

Eligibility Criteria

Inclusion

  • Patient who meets diagnosis of Panic Disorder (with or without Agoraphobia) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV).
  • Patients must have experienced at least 4 panic attacks within 4 weeks before screening.
  • At baseline patients with Panic Disorder of total score of 18 or higher on the Panic and Agoraphobia scale (clinician rated version).

Exclusion

  • Patients who concurrently have bipolar disorder, schizophrenia, delusional disorder, epilepsy, Major Depression Disorder (MDD), Obsessive Compulsive Disorder (OCD), Seasonal Affective Disorder (SAD) or General Anxiety Disorder (GAD) according to the DSM-IV criteria.
  • Patients who concurrently have depression/depressive state, anxiety disorder and generalized anxiety disorder may be included in the study if the primary diagnosis is identified to be panic disorder
  • Patients with the total score of at least 18 on the Hamilton Depression Rating Scale (HAM-D) (Items 1 to 17) at the start of Screening (Visit 1)
  • Patients who require concomitant drug therapy with psychotropic agents (including benzodiazepines) and monoamine oxidase inhibitor during the period of the study.

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2010

Estimated Enrollment :

321 Patients enrolled

Trial Details

Trial ID

NCT00677352

Start Date

May 1 2008

End Date

February 1 2010

Last Update

January 27 2021

Active Locations (22)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (22 locations)

1

Pfizer Investigational Site

Nagoya, Aichi-ken, Japan

2

Pfizer Investigational Site

Fukuoka, Fukuoka, Japan

3

Pfizer Investigational Site

Kitakyushu-shi, Fukuoka, Japan

4

Pfizer Investigational Site

Kitakyusyu-shi, Fukuoka, Japan